πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated β€” grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≀24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β€” use filters for patent-cliff planning.

Page 133 of 173

  1. US 7485317

    Thermo-reversible polymer for intralumenal implant

    Expires Mon Jan 29 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 7485451

    Storage stable compositions of biological materials

    Expires Mon Jan 29 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 7485627

    Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation

    Expires Mon Jan 29 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 7485307

    Human cystathionine Ξ²-synthase variants and methods of production thereof

    Expires Mon Jan 29 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 7482331

    Diagnosis and treatment of myocardial failure

    Expires Mon Jan 22 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 7482319

    Vault and vault-like carrier molecules

    Expires Mon Jan 22 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 7482150

    Virulent systemic feline calicivirus

    Expires Mon Jan 22 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 7479551

    Modified vitamin K-dependent polypeptides

    Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 7479550

    Amyloid Ξ² gene vaccines

    Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 7479579

    Triple transgenic mouse model of Alzheimer's disease

    Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 7476257

    Methods to engineer stratified cartilage tissue

    Expires Mon Jan 08 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 7473772

    Chimeric GB virus B (GBV-B)

    Expires Mon Jan 01 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 7470659

    Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)

    Expires Mon Dec 25 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 7470420

    Optical determination of glucose utilizing boronic acid adducts

    Expires Mon Dec 25 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 7470660

    Treatment for dark adaptation

    Expires Mon Dec 25 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 7470776

    Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof

    Expires Mon Dec 25 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 7470431

    Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer

    Expires Mon Dec 25 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 7468379

    Inhibition of osteolytic lesions by SRC kinase inhibitors

    Expires Mon Dec 18 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 7468426

    Oncoprotein protein kinase antibody kit

    Expires Mon Dec 18 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 7468432

    Cobalamin conjugates useful as antitumor agents

    Expires Mon Dec 18 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 7465716

    Targeted drug delivery with a hyaluronan ligand

    Expires Mon Dec 11 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 7465784

    Antimicrobial peptides and methods of identifying the same

    Expires Mon Dec 11 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 7465449

    Anti-Ξ±vΞ²6 antibodies

    Expires Mon Dec 11 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 7462691

    Mouse prostate stem cell antigen and uses thereof

    Expires Mon Dec 04 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 7462609

    Narcistatin prodrugs

    Expires Mon Dec 04 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 7462603

    Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery

    Expires Mon Dec 04 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 7462345

    Radionuclide labeling of vitamin B12 and coenzymes thereof

    Expires Mon Dec 04 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 7459439

    Granulysin peptides and methods of use thereof

    Expires Mon Nov 27 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 7459156

    Antibodies that mimic actions of neurotrophins

    Expires Mon Nov 27 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 7459534

    Inactivation resistant factor VIII

    Expires Mon Nov 27 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 7459601

    Human Ξ± synuclein expressing transgenic mice

    Expires Mon Nov 27 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 7455845

    Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure

    Expires Mon Nov 20 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 7455833

    Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids

    Expires Mon Nov 20 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 7455964

    Genes from the 20q13 amplicon and their uses

    Expires Mon Nov 20 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 7452964

    Compositions and methods of use of targeting peptides against placenta and adipose tissues

    Expires Mon Nov 13 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 7452971

    Compositions and methods for modifying toxic effects of proteinaceous compounds

    Expires Mon Nov 13 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 7452538

    Death domain containing receptor 4 antibodies and methods

    Expires Mon Nov 13 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 7452898

    Phosphonate compounds

    Expires Mon Nov 13 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 7452681

    Diagnostic methods for the detection of autism spectrum disorder

    Expires Mon Nov 13 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 7449444

    Hydroxyethyl starch-containing polypeptide compositions

    Expires Mon Nov 06 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 7449171

    Measurement of biosynthesis and breakdown rates of biological molecules that are inaccessible or not easily accessible to direct sampling, non-invasively, by label incorporation into metabolic derivatives and catabolic products

    Expires Mon Nov 06 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 7449192

    Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction

    Expires Mon Nov 06 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 7449323

    Hemorrhagic feline calicivirus

    Expires Mon Nov 06 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 7445628

    Method of treating a patient with a coated implantable medical device

    Expires Mon Oct 30 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 7446185

    Her2/neu target antigen and use of same to stimulate an immune response

    Expires Mon Oct 30 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 7445794

    Methods for treating human proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors

    Expires Mon Oct 30 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 7446124

    Wortmannin analogs and methods of using same in combination with chemotherapeutic agents

    Expires Mon Oct 30 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 7446182

    Recombinant antibodies for the detection and neutralization of anthrax toxin

    Expires Mon Oct 30 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.